Insulin Aspart (rDNA) USP
Composition: Mypart Penset: Each ml solution contains Insulin Aspart (rDNA) USP 100IU (equivalent to 3.5mg).
Indications: Insulin Aspart is an insulin analogue indicated to improve glycemic control in patients with diabetes mellitus.
Dosage and administration: Insulin Aspart has a faster onset and a shorter duration of action than soluble human insulin. Due to the faster onset of action, Insulin Aspart should generally be given immediately before a meal. When necessary Insulin Aspart may be given soon after a meal.
Dosage of Insulin Aspart is individual and determined on the basis of the physician's advice in accordance with the needs of the patient. It should normally be used in combination with long-acting insulin given at least once a day. The individual insulin requirement is usually between 0.5 and 1.0 IU/kg/day in adults and children over 2 years of age. In a meal-related treatment 50-70% of this requirement may be
provided by Insulin Aspart and the remainder by long-acting insulin. Adjustment of dosage may also be necessary if patients undertake increased physical activity or change their usual diet. Exercise taken immediately after a meal may increase the risk of hypoglycaemia.
Insulin Aspart should be administered by subcutaneous injection in the abdominal region, buttocks, thigh, or upper arm. Injection sites should be rotated within the same region from one injection to the next to reduce the risk of lipodystrophy. Because Insulin Aspart has a more rapid onset and a shorter duration of activity than human regular insulin, it should be injected immediately(within 5-10 minutes) before a meal.
Continuous Subcutaneous Insulin Infusion (CSII) by External
Insulin Aspart can also be infused subcutaneously by an external insulin pump. The initial programming of the external insulin infusion pump should be based on the total daily insulin dose of the previous regimen. Approximately 50% of the total dose is usually given as meal-related boluses of Insulin Aspart and the remainder is given as a basal infusion. When used with an infusion pump Insulin Aspart should not be mixed with any other insulin.
Insulin Aspart can be administered intravenously under medical supervision for glycemic control with close monitoring of blood glucose and potassium levels to avoid hypoglycaemia and hypokalaemia. For intravenous use, Insulin Aspart should be used at concentrations from 0.05 IU/ml to 1.0 IU/ml Insulin Aspart in infusion systems using polypropylene infusion bags. Insulin Aspart has been shown to be stable in infusion fluids such as 0.9% sodium chloride. Or, as directed by the registered physician.
Use in pregnancy and lactation: Pregnancy: Pregnancy category B.
Lactation: There are no restrictions on treatment with Insulin Aspart during lactation. Insulin treatment of the nursing mother should not affect the baby. However, dosage may need to be adjusted.
Packing: Mypart Penset: Each box contains 3x3ml glass cartridges.